Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheolmin Kim

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Ebiomedicine|February 9, 2025
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteersThomas R Moench, Lakshmi Botta, Brian Farrer, et al.
Biochemical and Biophysical Research Communications|June 13, 2021
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantDong-Kyun Ryu, Rina Song, Minsoo Kim, et al.
Emerging Microbes & Infections|August 25, 2022
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Ji-Min Seo, Bobin Kang, Rina Song, et al.
Biochemical and Biophysical Research Communications|September 21, 2021
The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2Dong-Kyun Ryu, Bobin Kang, Hanmi Noh, et al.
Cancer Research and Treatment|April 26, 2018
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer PatientsSe-Hoon Lee, Boram Lee, Joon Ho Shim, et al.
Nature Communications|January 13, 2021
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinCheolmin Kim, Dong-Kyun Ryu, Jihun Lee, et al.
Science (New York, N.Y.)|September 23, 2021
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium studyKathryn M Hastie, Haoyang Li, Daniel Bedinger, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Ebiomedicine|February 9, 2025
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteersThomas R Moench, Lakshmi Botta, Brian Farrer, et al.
Biochemical and Biophysical Research Communications|June 13, 2021
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantDong-Kyun Ryu, Rina Song, Minsoo Kim, et al.
Emerging Microbes & Infections|August 25, 2022
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Ji-Min Seo, Bobin Kang, Rina Song, et al.
Biochemical and Biophysical Research Communications|September 21, 2021
The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2Dong-Kyun Ryu, Bobin Kang, Hanmi Noh, et al.
Cancer Research and Treatment|April 26, 2018
Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer PatientsSe-Hoon Lee, Boram Lee, Joon Ho Shim, et al.
Nature Communications|January 13, 2021
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinCheolmin Kim, Dong-Kyun Ryu, Jihun Lee, et al.
Science (New York, N.Y.)|September 23, 2021
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium studyKathryn M Hastie, Haoyang Li, Daniel Bedinger, et al.
Pageof 4